Use of HDAC inhibitors for the treatment of myeloma

Details for Australian Patent Application No. 2006278718 (hide)

Owner Novartis AG

Inventors Atadja, Peter W.

Agent Davies Collison Cave

Pub. Number AU-B-2006278718

PCT Pub. Number WO2007/019116

Priority 60/705,226 03.08.05 US

Filing date 1 August 2006

Wipo publication date 15 February 2007

Acceptance publication date 7 October 2010

International Classifications

A61K 31/4045 (2006.01)

A61K 31/165 (2006.01) - having aromatic rings, e.g. colchicine, atenolol, progabide

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

28 February 2008 PCT application entered the National Phase

  PCT publication WO2007/019116 Priority application(s): WO2007/019116

7 October 2010 Application Accepted

  Published as AU-B-2006278718

3 February 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006278736-Coupling assemblies for spinal implants

2006278717-Conductive adhesives and biomedical articles including same